Editorial
doi: 10.1136/bmj.324.7349.1287.
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
- PMID: 12039807
- PMCID: PMC1123260
- DOI: 10.1136/bmj.324.7349.1287
Item in Clipboard
Editorial
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ.
.
Erratum in
- BMJ 2002 Jun 29;324(7353):1538
No abstract available
Figures
Main results according to published report (top) and pre-specified protocol (bottom). Alternate definition of ulcer related complications, pre-specified by the FDA, included more stringent criteria to address serious gastrointestinal bleeding. P values are from log rank tests.
Kaplan-Meier estimates for ulcer complications according to traditional definition. Results are truncated after 12 months, no ulcer complications occurred after this period. Adapted from Lu 2001.
Comment in
-
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.BMJ. 2002 Jul 20;325(7356):161; author reply 161. BMJ. 2002. PMID: 12130617 Free PMC article. No abstract available.
-
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.BMJ. 2002 Jul 20;325(7356):161; author reply 161. BMJ. 2002. PMID: 12134853 No abstract available.
-
Are selective COX 2 inhibitors superior to traditional NSAIDs? Little is known about COX 2 inhibitors.BMJ. 2002 Jul 20;325(7356):161; author reply 161. BMJ. 2002. PMID: 12134854 No abstract available.
-
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.BMJ. 2002 Jul 20;325(7356):161; author reply 161. BMJ. 2002. PMID: 12134855 No abstract available.
-
[Treatment of osteoarthritis with COX-2 inhibitors: good for the stomach, but bad for the patient?].Ugeskr Laeger. 2002 Aug 12;164(33):3874-5. Ugeskr Laeger. 2002. PMID: 12216163 Danish. No abstract available.
-
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.BMJ. 2003 Feb 8;326(7384):334; author reply 334. BMJ. 2003. PMID: 12574052 Free PMC article. No abstract available.
-
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.BMJ. 2003 Feb 8;326(7384):334; author reply 334. BMJ. 2003. PMID: 12575714 No abstract available.
Similar articles
-
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.Ann Intern Med. 2003 May 20;138(10):I39. doi: 10.7326/0003-4819-138-10-200305200-00003. Ann Intern Med. 2003. PMID: 12755582 No abstract available.
-
COX-2 inhibitors. Magic bullets or merely mortal?Harv Health Lett. 2000 Feb;25(4):4. Harv Health Lett. 2000. PMID: 10637015 No abstract available.
-
[Clinical use of COX-2 inhibitors].Vojnosanit Pregl. 2001 May-Jun;58(3):283-95. Vojnosanit Pregl. 2001. PMID: 11548555 Review. Serbian. No abstract available.
-
Celecoxib: a COX-2 inhibitor.Am J Manag Care. 1999 Apr;5(4):511-8; quiz 522-4. Am J Manag Care. 1999. PMID: 10387389 No abstract available.
-
What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Clin Exp Rheumatol. 2001. PMID: 11695246 Review.
Cited by
-
COX-2 inhibitors: a CLASS act or Just VIGORously promoted.MedGenMed. 2004 Mar 23;6(1):6. MedGenMed. 2004. PMID: 15208519 Free PMC article. Review.
-
Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study.BMJ. 2020 Oct 27;371:m3764. doi: 10.1136/bmj.m3764. BMJ. 2020. PMID: 33109515 Free PMC article.
-
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.Mol Cancer. 2006 May 18;5:19. doi: 10.1186/1476-4598-5-19. Mol Cancer. 2006. PMID: 16707021 Free PMC article.
-
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Gut. 2003 Apr;52(4):600-8. doi: 10.1136/gut.52.4.600. Gut. 2003. PMID: 12631678 Free PMC article. Review.
-
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.Arthritis Res Ther. 2003;5(1):28-31. doi: 10.1186/ar617. Epub 2002 Dec 11. Arthritis Res Ther. 2003. PMID: 12716445 Free PMC article.
References
-
- Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255. - PubMed
-
- Okie S. Missing data on Celebrex. Full study altered picture of drug. Washington Post 2001;5 Aug:A11.
-
- Berg Hrachovec J, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398. - PubMed
-
- Wright JM, Perry TL, Bassett KL, Chambers KG. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398–2399. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
